Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 49Breast 5Thoracic 2Plasma cell 2Tumor-Agnostic 1Other neoplasm 1Head & Neck 1

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Biopsy 9fludarabine phosphate 8Busulfan 8Whole-Body Irradiation 7Surveys and Questionnaires 6Mycophenolic Acid 6Educational Status 6Early Intervention, Educational 6Carboplatin 6fludarabine 5Tacrolimus 5Paclitaxel 5Methotrexate 5Methods 5Melphalan 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Colposcopy 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4Selenium 4Radiotherapy 4Patient Reported Outcome Measures 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × radium Ra 223 dichloride × Other neoplasm × Clear all
NCT04090398 2026-05-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled
BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡